Melanoma Mutagenesis and Aberrant Cell Signaling | Zendy

Danielle M. Bello | Zendy; Charlotte E. Ariyan | Zendy; Richard D. Carvajal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Melanoma Mutagenesis and Aberrant Cell Signaling

Author(s) -

Danielle M. Bello,

Charlotte E. Ariyan,

Richard D. Carvajal

Publication year - 2013

Publication title -

cancer control

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.794

H-Index - 72

eISSN - 1526-2359

pISSN - 1073-2748

DOI - 10.1177/107327481302000404

Subject(s) - gnaq , melanoma , cancer research , medicine , neuroblastoma ras viral oncogene homolog , mapk/erk pathway , targeted therapy , kinase , cancer , signal transduction , receptor tyrosine kinase , mutation , biology , microbiology and biotechnology , receptor , genetics , gene , colorectal cancer , kras

Malignant melanoma is the most fatal type of skin cancer. Traditional melanoma classification has been based on histological subtype or anatomical location. However, recent evidence suggests that melanoma comprises a group of diseases characterized by distinct molecular mutations. These mutations affect disease behavior but provide unique opportunities for targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research